Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X:
“Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
“Among patients who had been alive and progression-free at 3 years, 10-year melanoma-specific survival was 96% with nivolumab plus ipilimumab, 97% with nivolumab, and 88% with ipilimumab”
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
Authors: Jedd D. Wolchok et al.
